CA - Bausch + Lomb wins FDA nod for eye surgery product
2024-01-08 08:31:17 ET
More on Bausch Health, Bausch + Lomb, etc.
- Bausch Health: $20bn Debt Is A Mighty Elephant In The Room
- Bausch + Lomb: Not A Good Time To Buy (Rating Downgrade)
- Bausch Health Companies Inc. (BHC) Q3 2023 Earnings Call Transcript
- Bausch reports positive Phase 2 data for ulcerative colitis drug
- Bausch Health swings to quarterly loss on goodwill impairments, higher expenses
For further details see:
Bausch + Lomb wins FDA nod for eye surgery product